The Frequency of Low Muscle Mass and Its Overlap With Low Bone Mineral Density and Lipodystrophy in Individuals With HIV-A Pilot Study Using DXA Total Body Composition Analysis

Journal of Clinical Densitometry

Volumn 15, Issue 2, 2012, Pages 224-232

  Buehring, Bjoern ^a,b   Kirchner, Elizabeth ^b   Sun, Zhiyuan ^b   Calabrese, Leonard ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Body composition; HIV; Lipodystrophy; Osteoporosis; Sarcopenia

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; ADULT; BODY COMPOSITION; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LOGISTIC MODELS; MALE; MUSCLE, SKELETAL; PILOT PROJECTS; RISK FACTORS; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 84860497910     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.10.003     Document Type: Article

References (71)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372(9635):293-299. Antiretroviral Therapy Cohort Collaboration.
2. Hariri S., McKenna M.T. Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev 2007, 20(3):478-488.
3. Martin J., Volberding P. HIV and premature aging: a field still in its infancy. Ann Intern Med 2010, 153(7):477-479.
4. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155.
5. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352(1):48-62.
6. McComsey G.A., Tebas P., Shane E., et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010, 51(8):937-946.
7. Young B., Dao C.N., Buchacz K., et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011, 52(8):1061-1068.
8. Borderi M., Gibellini D., Vescini F., et al. Metabolic bone disease in HIV infection. AIDS 2009, 23(11):1297-1310.
9. Vance D.E., Childs G., Moneyham L., McKie-Bell P. Successful aging with HIV. J Gerontol Nurs 2009, 35(9):19-25.
10. Authier F.J., Chariot P., Gherardi R.K. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005, 32(3):247-260.
11. Lichtenstein K.A. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005, 39(4):395-400.
12. McDermott A.Y., Shevitz A., Knox T., et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001, 74(5):679-686.
13. Brown T.T., Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20(17):2165-2174.
14. Cazanave C., Dupon M., Lavignolle-Aurillac V., et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008, 22(3):395-402.
15. Collin F., Duval X., Le Moing V., et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009, 23(8):1021-1024.
16. Yin M.T., Glesby M.J. Low bone mineral density, HIV infection, and women: fracture or fiction?. Clin Infect Dis 2006, 42(7):1021-1023.
17. Brown T.T., McComsey G.A., King M.S., et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51(5):554-561.
18. Hoy J. Bone, fracture and frailty. Curr Opin HIV AIDS 2011, 6(4):309-314.
19. Brown T.T., Xu X., John M., et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther 2009, 6:8.
20. Carr A., Emery S., Law M., et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003, 361(9359):726-735.
21. Dinges W.L., Chen D., Snell P.G., et al. Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med 2005, 53(1):15-25.
22. Falutz J. Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007, 3(9):651-661.
23. Moreno S., Miralles C., Negredo E., et al. Disorders of body fat distribution in HIV-1-infected patients. AIDS Rev 2009, 11(3):126-134.
24. Tien P.C., Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 2004, 17(1):27-32.
25. Roubenoff R. Acquired immunodeficiency syndrome wasting, functional performance, and quality of life. Am J Manag Care 2000, 6(9):1003-1016.
26. Wilson I.B., Jacobson D.L., Roubenoff R., et al. Changes in lean body mass and total body weight are weakly associated with physical functioning in patients with HIV infection. HIV Med 2002, 3(4):263-270.
27. Scott W.B., Oursler K.K., Katzel L.I., et al. Central activation, muscle performance, and physical function in men infected with human immunodeficiency virus. Muscle Nerve 2007, 36(3):374-383.
28. Estanislao L., Thomas D., Simpson D. HIV neuromuscular disease and mitochondrial function. Mitochondrion 2004, 4(2-3):131-139.
29. Deeks S.G., Phillips A.N. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009, 338:a3172.
30. Rosenberg I.H. Epidemiologic and methodologic problems in determining nutritional status of older persons. Am J Clin Nutr 1989, 50(Suppl):1231-1233. [summary comments].
31. Rosenberg I.H. Sarcopenia: origins and clinical relevance. J Nutr 1997, 127(5 Suppl):990S-991S.
32. Lang T., Streeper T., Cawthon P., et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2009, 21(4):543-559.
33. Rolland Y., Czerwinski S., Abellan Van Kan G., et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008, 12(7):433-450.
34. Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev 2007, 65(12 Pt 2):S208-S212.
35. Bauer J.M., Sieber C.C. Sarcopenia and frailty: a clinician's controversial point of view. Exp Gerontol 2008, 43(7):674-678.
36. Delmonico M.J., Harris T.B., Lee J.S., et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 2007, 55(5):769-774.
37. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39(4):412-423.
38. Muscaritoli M., Anker S.D., Argiles J., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) " cachexia-anorexia in chronic wasting diseases" and " nutrition in geriatrics" . Clin Nutr 2010, 29(2):154-159.
39. Glass D., Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci 2010, 1211:25-36.
40. Sokka T., Hakkinen A. Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases. Clin Exp Rheumatol 2008, 26(5 Suppl 51):S14-S20.
41. Warburton D.E., Nicol C.W., Bredin S.S. Health benefits of physical activity: the evidence. CMAJ 2006, 174(6):801-809.
42. Marcus E.N. Bones of contention: premature aging and bone loss emerge as new concerns with HIV. Posit Aware 2011, 23(1):28-29.
43. Desquilbet L., Margolick J.B., Fried L.P., et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 2009, 50(3):299-306.
44. Onen N.F., Overton E.T. A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. Curr Aging Sci 2011, 4(1):33-41.
45. Scherzer R., Heymsfield S.B., Lee D., et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011, 25(11):1405-1414.
46. Bolland M.J., Grey A.B., Horne A.M., et al. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf) 2007, 67(2):270-275.
47. Degris E., Delpierre C., Sommet A., et al. Longitudinal study of body composition of 101 HIV men with lipodystrophy: dual-energy X-ray criteria for lipodystrophy evolution. J Clin Densitom 2010, 13(2):237-244.
48. Tsekes G., Chrysos G., Douskas G., et al. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 2002, 3(2):85-90.
49. Bonnet E., Delpierre C., Sommet A., et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 2005, 8(3):287-292.
50. Delpierre C., Bonnet E., Marion-Latard F., et al. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. J Clin Densitom 2007, 10(4):376-380.
51. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4(6):368-381.
52. Cavalcanti R.B., Cheung A.M., Raboud J., Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom 2005, 8(3):293-297.
53. Freitas P., Santos A.C., Carvalho D., et al. Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom 2010, 13(2):197-203.
54. Baumgartner R.N., Koehler K.M., Gallagher D., et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998, 147(8):755-763.
55. Janssen I., Baumgartner R.N., Ross R., et al. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004, 159(4):413-421.
56. Gallagher D., Visser M., De Meersman R.E., et al. Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. J Appl Physiol 1997, 83(1):229-239.
57. Newman A.B., Kupelian V., Visser M., et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003, 51(11):1602-1609.
58. Montano M., Flanagan J.N., Jiang L., et al. Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab 2007, 92(7):2793-2802.
59. Yarasheski K.E., Scherzer R., Kotler D.P., et al. Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. J Gerontol A Biol Sci Med Sci 2011, 66(3):332-340.
60. Cawthon P.M., Fox K.M., Gandra S.R., et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults?. J Am Geriatr Soc 2009, 57(8):1411-1419.
61. Di Monaco M., Vallero F., Di Monaco R., Tappero R. Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. Arch Gerontol Geriatr 2011, 52(1):71-74.
62. Binkley N., Buehring B. Beyond FRAX: it's time to consider " sarco-osteopenia" . J Clin Densitom 2009, 12(4):413-416.
63. Lang T., Cauley J.A., Tylavsky F., et al. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res 2010, 25(3):513-519.
64. Lauretani F., Russo C.R., Bandinelli S., et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003, 95(5):1851-1860.
65. Visser M., Goodpaster B.H., Kritchevsky S.B., et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005, 60(3):324-333.
66. Clark B.C., Manini T.M. Functional consequences of sarcopenia and dynapenia in the elderly. Curr Opin Clin Nutr Metab Care 2010, 13(3):271-276.
67. Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 2006, 54(1):56-62.
68. Grinspoon S., Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis 2003, 36(Suppl 2):S69-S78.
69. Wanke C.A., Silva M., Knox T.A., et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 31(3):803-805.
70. Richert L., Dehail P., Mercie P., et al. High frequency of poor locomotor performance in HIV-infected patients. AIDS 2011, 25(6):797-805.
71. Yao J., Yu W., Li T., et al. The pilot study of DXA assessment in Chinese HIV-infected men with clinical lipodystrophy. J Clin Densitom 2011, 14(1):58-62.